Mankind Pharma

Why is Mankind Pharma Ltd falling/rising?

As of 30-Jul, Mankind Pharma Ltd's stock price is at 2,576.95, down 0.6% recently. Despite short-term declines, the stock has appreciated 17.33% year-to-date and shows increasing investor interest, indicating potential long-term growth.

As of 30-Jul, Mankind Pharma Ltd's stock price is currently at 2,576.95, reflecting a decrease of 15.6 points or 0.6%. The stock has been underperforming recently, having fallen consecutively for the last two days, resulting in a total decline of 1.57% during this period. Additionally, the stock's performance today has underperformed its sector by 0.29%.<BR><BR>Despite these recent declines, Mankind Pharma has shown some positive indicators over longer periods. For instance, year-to-date, the stock has appreciated by 17.33%, significantly outperforming the Sensex, which has decreased by 8.56% during the same timeframe. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally upward trend over a longer horizon.<BR><BR>Investor participation appears to be increasing, as evidenced by a delivery volume of 2.07 lacs on July 29, which is up by 28.43% compared to the 5-day average. This suggests that while the stock is currently facing short-term challenges, there is a growing interest among investors.<BR><BR>In summary, Mankind Pharma Ltd is experiencing a short-term decline in its stock price due to recent underperformance and consecutive losses, but it has shown strong year-to-date growth and increasing investor participation, which may support its long-term prospects.

Which are the latest news on Mankind Pharma?

Should I buy, sell or hold Mankind Pharma Ltd?

When is the next results date for Mankind Pharma Ltd?

The next results date for Mankind Pharma Ltd is 30 July 2026.

The next results date for Mankind Pharma Ltd is scheduled for 30 July 2026.

What does Mankind Pharma do?

Mankind Pharma Ltd is a mid-cap pharmaceutical company established in 1991, reporting net sales of ₹3,443 Cr and a net profit of ₹554 Cr for the quarter ending March 2026. Key financial metrics include a P/E ratio of 48.00 and a market cap of ₹99,057 Cr.

Overview: <BR>Mankind Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History: <BR>Mankind Pharma Limited was incorporated in 1991 as a Private Limited Company and later converted to a Public Limited Company in 2005. The latest quarterly results report net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3,443 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 554 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 99,057 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 48.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.04% <BR>Debt Equity: 0.26 <BR>Return on Equity: 12.39% <BR>Price to Book: 6.05 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Mankind Pharma?

As of 10th June, Mankind Pharma Ltd has a market capitalization of 99,057.00 Cr, with net sales of 14,277.64 Cr and a net profit of 1,912.93 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Mankind Pharma Ltd has a market capitalization of 99,057.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 14,277.64 Cr, while the sum of Net Profit for the same period is 1,912.93 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds amount to 14,332.39 Cr, and Total Assets are valued at 27,651.64 Cr.

Who are in the management team of Mankind Pharma?

The management team of Mankind Pharma includes Ramesh Chand Juneja (Chairman), Rajeev Juneja (Vice Chairman), Sheetal Arora (CEO), and several independent directors, all of whom guide the company's strategic direction and operations.

The management team of Mankind Pharma includes the following key members:<BR><BR>1. **Ramesh Chand Juneja** - Chairman & Wholetime Director<BR>2. **Rajeev Juneja** - Vice Chairman & Managing Director<BR>3. **Sheetal Arora** - Whole Time Director & CEO<BR>4. **Tilokchand Punamchand Ostwal** - Independent Director<BR>5. **Pradeep Chugh** - Company Secretary & Compliance Officer<BR>6. **Bharat Anand** - Independent Director<BR>7. **Satish Kumar Sharma** - Whole-time Director<BR>8. **Vivek Kalra** - Independent Director<BR>9. **Vijaya Sampath** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Mankind Pharma?

Mankind Pharma's peers include Torrent Pharma, Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Aurobindo Pharma, Laurus Labs, Biocon, Alkem Lab, and Glenmark Pharma. Mankind Pharma exhibits excellent management and growth, with a 1-year return of 0.75%, outperforming Cipla but underperforming Laurus Labs, which has the highest return at 106.63%.

Peers: The peers of Mankind Pharma are Torrent Pharma, Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Aurobindo Pharma, Laurus Labs, Biocon, Alkem Lab, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Torrent Pharma, Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, and Alkem Lab, while Average management risk is found at Aurobindo Pharma and Biocon. Growth is Excellent for Zydus Lifesci., Lupin, and Mankind Pharma, while Average growth is seen at Torrent Pharma and Dr Reddy's Labs, and Below Average growth is noted for Cipla, Aurobindo Pharma, Laurus Labs, and Alkem Lab, and the rest. Capital Structure is Excellent for Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, and Alkem Lab, while Good capital structure is found at Torrent Pharma and Glenmark Pharma, and Below Average capital structure is observed at Laurus Labs and Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 106.63%, while Cipla has the lowest at -8.95%, with Mankind Pharma's 1-year return at 0.75% being higher than Cipla's but lower than Laurus Labs'. Additionally, Aurobindo Pharma, Laurus Labs, and Alkem Lab have negative six-month returns.

Are Mankind Pharma Ltd latest results good or bad?

Mankind Pharma Ltd's latest results show strong profit growth and improved margins, with a net profit of ₹554.35 crores for Q4 FY26, but a revenue decline raises concerns about sustainability. Additionally, the company's high valuation at a price-to-earnings ratio of 53 may indicate challenges in maintaining aggressive growth expectations.

Mankind Pharma Ltd's latest results present a mixed picture. On the positive side, the company reported a significant net profit of ₹554.35 crores for Q4 FY26, which reflects a robust growth of 35.62% quarter-on-quarter and 31.75% year-on-year. This indicates strong operational leverage and effective cost management, particularly with operating margins reaching a multi-quarter high of 27.01%.<BR><BR>However, there are concerns regarding revenue, which declined by 3.48% sequentially to ₹3,442.93 crores. Although the year-on-year revenue growth of 11.81% is commendable, it falls short of the company's historical growth rates. This decline raises questions about the sustainability of demand and whether the recent profit growth can be maintained.<BR><BR>Additionally, the company's valuation is a significant concern, trading at a price-to-earnings ratio of 53, well above the pharmaceutical industry average of 35. This premium suggests that the market is expecting aggressive future growth, which may be challenging to achieve consistently.<BR><BR>In summary, while Mankind Pharma's profit growth and margin expansion are impressive, the revenue decline and high valuation create a cautious outlook for potential investors.

Is Mankind Pharma technically bullish or bearish?

As of December 1, 2025, the technical trend has shifted to a bearish stance, driven by bearish MACD and Bollinger Bands signals, despite a bullish weekly RSI, with the stock trading below its previous close and well off its 52-week high.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands on both weekly and monthly timeframes, and a bearish moving average on the daily timeframe. The weekly RSI is bullish, but this is overshadowed by the overall bearish trend in other indicators. The KST is mildly bearish, and there is no clear trend indicated by Dow Theory or OBV. Overall, the bearish sentiment is reinforced by the recent price action, with the stock trading below its previous close and significantly off its 52-week high.

How has been the historical performance of Mankind Pharma?

Mankind Pharma has shown consistent growth, with net sales increasing from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025, alongside rising profits and improved cash flow. Total assets surged from INR 6,323.62 crore to INR 27,651.64 crore during the same period.

Answer:<BR>The historical performance of Mankind Pharma shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Mankind Pharma's net sales have increased significantly from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. The total expenditure, excluding depreciation, also grew from INR 4,566.33 crore in March 2021 to INR 9,189.51 crore in March 2025, indicating rising operational costs. Operating profit (PBDIT) has shown a positive trend, climbing from INR 1,819.05 crore in March 2021 to INR 3,554.72 crore in March 2025. Profit before tax increased from INR 1,679.93 crore in March 2021 to INR 2,504.09 crore in March 2025, while profit after tax rose from INR 1,281.35 crore to INR 1,994.35 crore during the same period. The company's total assets surged from INR 6,323.62 crore in March 2021 to INR 27,651.64 crore in March 2025, with total liabilities also increasing from INR 6,323.62 crore to INR 8,483.03 crore. The cash flow from operating activities improved from INR 1,137 crore in March 2021 to INR 2,413 crore in March 2025, reflecting enhanced operational efficiency. Overall, Mankind Pharma has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and cash flow.

Is Mankind Pharma overvalued or undervalued?

As of October 13, 2025, Mankind Pharma is considered very expensive with a PE ratio of 53.30 and significant underperformance compared to peers and the Sensex, indicating it may be overvalued.

As of 13 October 2025, Mankind Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on key financial ratios, including a PE ratio of 53.30, an EV to EBITDA of 33.50, and a Price to Book Value of 7.06. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Mankind Pharma's valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 34.9, while Cipla is valued attractively with a PE of 23.43. The disparity in valuations raises concerns about Mankind's sustainability at these levels. Furthermore, the company's stock has underperformed against the Sensex, with a year-to-date return of -15.1% compared to the Sensex's gain of 5.36%. This underperformance further supports the conclusion that Mankind Pharma is currently overvalued.

Who are the top shareholders of the Mankind Pharma?

The top shareholder of Mankind Pharma is the Ramesh Juneja Family Trust, holding 20.2%. Promoters own the majority, with institutional investors holding 20.59% combined, while individual investors own about 1.64%.

The top shareholders of Mankind Pharma include the Ramesh Juneja Family Trust, which holds the largest stake at 20.2%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. Additionally, institutional investors are involved, with 32 mutual fund schemes holding a combined 7.67% and 554 foreign institutional investors (FIIs) holding 12.92%. The highest public shareholder is the SBI Large & Midcap Fund, which holds 1.58%. Individual investors collectively own about 1.64% of the company.

Has Mankind Pharma declared dividend?

No Dividend History Available